Evidence map›Paper›PMID 29797327›Full record

ArticleBritish journal of haematology2018

Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia.

Ana M Hurtado, Gines Luengo-Gil, Tzu H Chen-Liang, Fabio Amaral, Kiran Batta, Laura Palomo, Eva Lumbreras, Bartlomiej Przychodzen, Eva Caparros, Marıa L Amigo and 11 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 3 countries.

Ana M HurtadoHaematology Department, Hospital Morales Meseguer, IMIB, Murcia, Spain.
Gines Luengo-GilHaematology Department, Hospital Morales Meseguer, IMIB, Murcia, Spain.
Tzu H Chen-LiangHaematology Department, Hospital Morales Meseguer, IMIB, Murcia, Spain.
Fabio AmaralLeukaemia Biology Laboratory, Cancer Research UK, Manchester Institute, University of Manchester, Manchester, UK.
Kiran BattaDivision of Cancer Sciences, Cancer Research UK, Manchester Institute, University of Manchester, Manchester, UK.
Laura PalomoJosep Carreras Leukaemia- Research Institute, ICO-Hospital Germans Trias i Pujol, Badalona, Spain.
Eva LumbrerasDepartment of Haematology, Hospital Universitario de Salamanca, Salamanca, Spain.
Bartlomiej PrzychodzenDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, USA.
Eva CaparrosHaematology Department, Hospital Morales Meseguer, IMIB, Murcia, Spain.
Marıa L AmigoHaematology Department, Hospital Morales Meseguer, IMIB, Murcia, Spain.
Maria Dıez-CampeloDepartment of Haematology, Hospital Universitario de Salamanca, Salamanca, Spain.
Lurdes ZamoraJosep Carreras Leukaemia- Research Institute, ICO-Hospital Germans Trias i Pujol, Badalona, Spain.
Eduardo J Salido FierrezDepartment of Haematology, Virgen de la Arrixaca University Hospital, IMIB, Murcia, Spain.
Jaroslaw P MaciejewskiDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, USA.
Francisco J OrtuñoHaematology Department, Hospital Morales Meseguer, IMIB, Murcia, Spain.
Vicente VicenteHaematology Department, Hospital Morales Meseguer, IMIB, Murcia, Spain.
Marıa Del CanizoDepartment of Haematology, Hospital Universitario de Salamanca, Salamanca, Spain.
Francesc SoleJosep Carreras Leukaemia- Research Institute, ICO-Hospital Germans Trias i Pujol, Badalona, Spain.
Francisca Ferrer-MarinHaematology Department, Hospital Morales Meseguer, IMIB-CIBERERUCAM, Murcia, Spain.
Daniel H WisemanLeukaemia Biology Laboratory, Cancer Research UK, Manchester Institute, University of Manchester, Manchester, UK.
Andres JerezHaematology Department, Hospital Morales Meseguer, IMIB, Murcia, Spain.
Hospital General Universitario Morales Meseguer · ESComplejo Hospitalario de Salamanca · ESJosep Carreras Leukaemia Research Institute · ESCancer Research UK Manchester Institute · GBCleveland Clinic · USHospital Universitario Virgen de la Arrixaca · ESUniversity of Manchester · GB

Funding

Therapeutic Implications of Molecular Defects in Bone Marrow FailureR35HL135795 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2017 to 2023
$5.7M
NHLBI NIH HHS R35 HL135795
6 · The paper itself

Abstract

Despite the absence of mutations in the DNA repair machinery in myeloid malignancies, the advent of high-throughput sequencing and discovery of splicing and epigenetics defects in chronic myelomonocytic leukaemia (CMML) prompted us to revisit a pathogenic role for genes involved in DNA damage response. We screened for misregulated DNA repair genes by enhanced RNA-sequencing on bone marrow from a discovery cohort of 27 CMML patients and 9 controls. We validated 4 differentially expressed candidates in CMML CD34

Indexed as

AgedBone MarrowCase-Control StudiesCyclin-Dependent Kinase Inhibitor p21DNA-Binding ProteinsDNA Mutational AnalysisDNA RepairEndonucleasesFemaleHigh-Throughput Nucleotide SequencingHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, ChronicMaleMiddle AgedBAP1 protein, humanCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21DNA-Binding ProteinsEndonucleasesERCC1 protein, humanPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Serine-Arginine Splicing FactorsSRSF2 protein, humanTumor Suppressor ProteinsUbiquitin ThiolesteraseCMML transcriptomecyclin dependent kinase inhibitor 1A (CDKN1A)excision repair cross-complementation group 1 (ERCC1)poly ADP-ribose polymerase 1 (PARP1)synthetic lethality

Identifiers

PMID29797327
PMCPMC8404555
OpenAlexW2803164837

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.